KalVista Pharmaceuticals (KALV) Misses Q3 EPS by 5c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q3 EPS of ($0.92), $0.05 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MagnaChip (MX) files $50M mixed shelf
• Nvidia pitches Vera CPU to Chinese clients with August delivery target